Point-Counterpoint: Meningitis/Encephalitis Syndromic Testing in the Clinical Laboratory

Area of Science:

• Clinical Microbiology
• Infectious Diseases
• Molecular Diagnostics

Background:

• FDA-cleared syndromic panels for pathogen detection emerged in 2008.
• The FilmArray meningitis/encephalitis panel is a recent advancement, detecting 14 targets within an hour.
• These panels target pathogens causing diverse symptoms within the same organ system.

Purpose of the Study:

• To present a debate on the unrestricted versus restricted use of multiplex syndromic panels in clinical laboratories.
• To discuss the advantages and disadvantages of offering advanced molecular diagnostic assays.

Main Methods:

• The study presents a Point-Counterpoint discussion between two experts.
• One expert advocates for unrestricted offering of syndromic panels.
• The other expert raises concerns regarding their use as first-line tests and suggests limitations.

Main Results:

• Studies report both false-positive and false-negative results with syndromic panels.
• The significant cost of these assays is a shared concern among healthcare systems.
• Healthcare systems employ varied strategies for assay availability, including restricted use or ordering specific PCRs.

Conclusions:

• The debate highlights the need for strategic implementation of syndromic panels.
• Consideration of cost, accuracy, and clinical utility is crucial for laboratory adoption.
• Balancing comprehensive testing with resource management remains a key challenge.